SecBot SecBot

INSM drug pipeline

INSMED Inc · 3 rated drugs
$121.16
+2.6% 1-day · Nov 13
Next catalyst
Jan 28, 2027
ARIKAYCE PDUFA date · in 73 days
Typical move on FDA news
±5.3%
1-day, median of 4 events
IV rank
No data
No current options data
Rated drugs
3
1 bullish · 2 neutral
Phase 3 trials
2
0 with results posted

Upcoming catalysts

2 dated
  1. Dec 31, 2026
    Treprostinil Palmitil
    Phase 3 primary completion
  2. Jan 28, 202773d
    ARIKAYCE
    PDUFA date · Mycobacterium avium complex (MAC) lung disease

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2018. Label expansion decision pending FDA review (sNDA submitted July 2026, no specific PDUFA date available).

ARIKAYCE amikacin liposome inhalation suspension Updated Sep 4

73days
Next catalyst
PDUFA date · Jan 28, 2027 · Mycobacterium avium complex (MAC) lung disease
What to watch

ARIKAYCE is a mature commercial asset for Insmed; the stock's primary driver is now BRINSUPRI's launch trajectory. Investors should watch for the FDA decision on ARIKAYCE's sNDA for label expansion to newly diagnosed MAC patients (timing unconfirmed), but the bigger stock-moving events will likely be BRINSUPRI sales updates and the Japan approval ramp.

Bull case
  • ARIKAYCE is the only FDA-approved treatment for refractory MAC lung disease, a serious condition with limited options, giving it a protected market position.
  • The sNDA for label expansion to newly diagnosed MAC patients (filed July 2026) could meaningfully expand the addressable patient population if approved.
  • Insmed raised combined peak revenue estimates for its three lead programs (BRINSUPRI, TPIP, ARIKAYCE) to >$14B, and ARIKAYCE 2026 revenue guidance of $450-470M provides a solid commercial base.
Bear case
  • ARIKAYCE now represents a smaller portion of Insmed's revenue mix, BRINSUPRI (brensocatib) drove $309.2M in Q2 2026 alone, making ARIKAYCE a secondary growth driver and diluting its stock-moving impact.
  • The drug carries a boxed FDA warning (added June 2026) for risk of increased respiratory adverse reactions including hypersensitivity pneumonitis and hemoptysis, which could limit uptake.
  • Competing treatment regimens for MAC lung disease (multi-drug antibiotic combinations) are standard of care and ARIKAYCE is approved only for refractory cases, limiting its current market.
▲ bullish
Impact
PhaseApproved
Time to marketAlready approved and commercially launched in the US (August 2025), EU (November 2025), and Japan (August 2026)

BRINSUPRI brensocatib Updated Sep 4

What to watch

BRINSUPRI is already a commercial success with a blockbuster launch trajectory, but the stock has pulled back ~40% from its 52-week high of $212.75. With no imminent binary catalyst (the drug is already approved globally), the investment thesis hinges on continued commercial execution and pipeline progress from Insmed's other assets (TPIP, ARIKAYCE). Watch quarterly prescription trends and any label-expansion updates for brensocatib.

Bull case
  • First and only FDA-approved treatment for NCFB, a large, untreated chronic lung disease population, giving Insmed a multi-year market monopoly
  • Commercial launch is accelerating rapidly: Q2 2026 BRINSUPRI revenue of $309.2M was up 49% sequentially, and full-year 2026 guidance was raised to $1.25B-$1.40B from 'at least $1B'
  • Overwhelming analyst support: 29 of 30 analysts rate Buy/Strong Buy, with a mean price target of ~$200 (56% upside from ~$126)
Bear case
  • BRINSUPRI failed Phase 2 trials in two additional indications (hidradenitis suppurativa and chronic rhinosinusitis), limiting label-expansion optionality
  • Significant insider selling: COO Roger Adsett sold ~$32M in stock on August 10, 2026, and CEO William Lewis also sold shares in July 2026; no insider open-market purchases in the last 90 days
  • Stock has fallen ~40% from its 52-week high of $212.75, currently trading at ~$126, suggesting the market is pricing in execution risk despite strong launch data
● neutral
Impact
PhaseNot stated
Time to marketNot stated

INS1033 Updated Sep 5

What to watch

There is no actionable information on "INS1033", it is not a known Insmed pipeline asset. Investors should monitor Insmed's corporate presentations and pipeline page for any new early-stage candidates, but no catalyst related to this drug name can be identified.

Bull case
  • Insmed (INSM) is a well-capitalized biopharma with an approved product (Arikayce) and strong analyst consensus: 29 Buy/Strong Buy ratings vs 1 Hold, with a mean price target of ~$200.
  • Institutional ownership is deep, FMR LLC ($1.7B), BlackRock ($1.7B), and Vanguard ($1.1B) are top holders as of Q2 2026 (per institutional holdings data).
  • Brensocatib (BRINSUPRI) recently received Japanese approval for NCFB, and the pipeline includes treprostinil palmitil in Phase 3 for PH-ILD.
Bear case
  • 'INS1033' is not a known Insmed pipeline asset, there is zero public information about this drug candidate, making it impossible to evaluate.
  • Insmed's stock has declined from a 52-week high of ~$213 to ~$126 (per stock price data), and short interest was ~5% of outstanding shares as of mid-August 2026.
  • The brensocatib Phase 2 CEDAR study in hidradenitis suppurativa was terminated, and the stock saw negative price reactions around prior clinical catalysts.

Other drugs in filings and trials

no drug report yet
  • treprostinil palmitil Last: Orphan drug designation · Jan 1, 2026 2 trials
  • ARIKAYCE KIT Last: Approval · Sep 28, 2018
  • OpSCF 1 trial
  • Treprostinil Palmitil Inhalation Powder 1 trial

Past FDA events & how the stock moved

4 events
DateDrugEvent1 day5 days
Feb 1, 2026BRINSUPRIClinical hold−1.8%−4.5%
Jan 1, 2026treprostinil palmitilOrphan drug designation+1.8%−2.2%
Aug 12, 2025BRINSUPRIApproval+8.8%+12.7%
Sep 28, 2018ARIKAYCE KITApproval−26.2%−19.1%

Clinical trials

7 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
Treprostinil PalmitilAn Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)Phase 3Active not recruiting91Dec 31, 2026
Treprostinil Palmitil Inhalation PowderAn Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Phase 3Completed31Apr 1, 2026
BRINSUPRIA Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)Phase 2Terminated214Feb 12, 2026
BRINSUPRIA Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)Phase 2Completed288Sep 30, 2025
Treprostinil PalmitilA Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial HypertensionPhase 2Completed102Mar 27, 2025
OpSCFPhase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis)Phase 2Completed · results50Sep 3, 2024
BRINSUPRIA Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic FibrosisPhase 2Completed · results29Nov 1, 2022